James Paul Scopa
CIK 1356950 · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$31.1K
Companies
6
Total Filings
47
Lifetime Open-Market Net
$1.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALGS | Director | 7,323 | $4.25 | $31.1K | $0 | 8 | 2026-06-29 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | Director | 333 | $4.36 | $1.5K | $297.7K | 15 | 2025-12-10 |
| DICE Therapeutics, Inc. (DICE) Delisted | Director | 0 | $47.55 | $0 | -$188.5K | 8 | 2023-08-09 |
| Histogen Inc. (CNAT) Delisted | Director | 101,010 | — | — | $1.82M | 5 | 2018-06-25 |
| TriVascular Technologies, Inc. (TRIV) Delisted | Director | 0 | — | — | $0 | 2 | 2016-02-04 |
| MEMY | 10%+ Owner | 0 | $17.05 | $0 | $0 | 1 | 2009-01-05 |
Recent Filings · Page 2 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-03 | DICE Therapeutics, Inc. (DICE) Delisted | Gift (G) | −2,420 | $0 | EDGAR |
| 2023-07-21 | ALGS | Grant (A) | — | $0 | EDGAR |
| 2023-07-19 | DICE Therapeutics, Inc. (DICE) Delisted | Gift (G) | −2,200 | $0 | EDGAR |
| 2023-07-13 | DICE Therapeutics, Inc. (DICE) Delisted | Gift (G) | −300 | $0 | EDGAR |
| 2023-06-13 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-02 | DICE Therapeutics, Inc. (DICE) Delisted | Gift (G) | — | $0 | EDGAR |
| 2023-03-21 | DICE Therapeutics, Inc. (DICE) Delisted | Mixed | −10,000 | -$290.5K | EDGAR |
| 2022-06-27 | ALGS | Grant (A) | — | $0 | EDGAR |
| 2022-06-14 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-08 | DICE Therapeutics, Inc. (DICE) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.